A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. - Kelly, R. J.; Thomas, A.; Rajan, A.; Chun, G.; Lopez-Chavez, A.; Szabo, E.; Spencer, S.; Carter, C. A.; Guha, U.; Khozin, S.; Poondru, S.; Van Sant, C.; et al. (Annals of Oncology, 2013)